Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
StatusCompleted No Results Posted
Indication/ConditionMajor Depressive Disorder
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
Inclusion Criteria: diagnosis of major depressive disorder consistent with DSM-IV-TR current episode greater than 8 weeks in duration Hamilton Depression score >/- 21 less than 25% reduction in depression during current episode assessed by ATRQ Exclusion Criteria: Axis diagnosis of other psychiatric disorders Experiencing hallucinations, delusions, other psychotic symptomatology ECT during current episode